Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
What role could emerging technologies, such as antimicrobial coatings or biofilm-disrupting agents, play in reducing the incidence of CIED infections?
Related Questions
What factors do you consider when deciding between monotherapy with an antipseudomonal cephalosporin and combination therapy in ICU patients with Pseudomonas aeruginosa bloodstream infection who are not in septic shock?
What is your approach in managing patients with suspected super-infected pancreatic pseudocysts that are not yet mature enough for drainage?
Would you consider leaving fever untreated in patients with sepsis to potentially enhance immune responses and antimicrobial efficacy?
How would you manage a frail but functioning elderly patient with extensive thoracolumbar spinal fusions 4-5 years ago now presenting with copious purulent drainage from L2-L4 whose MRI shows no osteomyelitis or abscess, and who has mild pain but no systemic signs or symptoms of illness?
What criteria should be used to determine the timing of placing central venous access or cardiac devices in patients with Staphylococcus lugdunensis infective endocarditis, considering the skip phenomenon?
How have the results of the BALANCE trial, which demonstrated the noninferiority of 7 days of antibiotics compared to 14 days for non-S. aureus bloodstream infections, influenced your practice?
Do you switch to an alternative agent for C difficile colitis for a patient with suspected infection and positive testing who continues to have >3 watery bowel movements daily despite multiple days of oral vancomycin treatment?
How would you approach troponin testing and cardiac monitoring for hospitalized patients with Mycoplasma pneumonia, given recent findings of significant cardiac involvement?
What factors do you consider when choosing between baloxavir and oseltamivir for treating patients with influenza?
What is your typical approach to antibiotic management for severe necrotizing MSSA pneumonia with concurrent MSSA bacteremia assuming no overt antibiotic contraindications and TTE without evidence of endocarditis?
